Feline VLP-1 antibody and antigen (recombinant protein)
Diagnostic anti-Feline VLP-1 antibodies pairs and antigen for animal health (animal Cat/Feline Alzheimer Disease(AD)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Neurodegenerative diseases diagnostics products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-FEL-VLP-1-Ag01 | Recombinant Feline VLP-1 protein | 3090 |
GMP-FEL-VLP-1-Ab01 | Anti-Feline VLP-1 mouse monoclonal antibody (mAb) | 1953 |
GMP-FEL-VLP-1-Ab02 | Anti-Feline VLP-1 mouse monoclonal antibody (mAb) | 1953 |
GMP-FEL-VLP-1-Ab03 | Anti-Feline VLP-1 human monoclonal antibody (mAb) | 1953 |
GMP-FEL-VLP-1-Ab04 | Anti-Feline VLP-1 human monoclonal antibody (mAb) | 1953 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. of Products | GMP-FEL-VLP-1-Ag01 |
Product Name | Recombinant Feline VLP-1 protein |
Target/Biomarker | Feline Visinin-like protein 1 () |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Feline Visinin-like protein 1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in level test of animal Cat/Feline with Alzheimer Disease(AD). |
Tag | His |
Products description | Recombinant Feline VLP-1 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-FEL-VLP-1-Ab01, GMP-FEL-VLP-1-Ab02 |
Product Name | Anti-Feline VLP-1 mouse monoclonal antibody (mAb) |
Target/Biomarker | Feline Visinin-like protein 1 () |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Feline Visinin-like protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies in level test of animal Cat/Feline with Alzheimer Disease(AD). |
Tag | mFc |
Products description | Anti-Feline VLP-1 mouse monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. of Products | GMP-FEL-VLP-1-Ab03, GMP-FEL-VLP-1-Ab04 |
Product Name | Anti-Feline VLP-1 human monoclonal antibody (mAb) |
Target/Biomarker | Feline Visinin-like protein 1 () |
Expression platform | CHO |
Isotypes | Human IgG1 |
Bioactivity validation | Recombinant Feline Visinin-like protein 1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies in level test of animal Cat/Feline with Alzheimer Disease(AD). |
Tag | hFc |
Products description | Anti-Feline VLP-1 human monoclonal antibody (mAb) is a monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti- antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker information
Feline Vaccinia-Like Particles-1 (VLP-1) stands as a captivating biomarker, residing at the intersection of feline immunology and viral mimicry. At its core, VLP-1 is a unique molecular structure that shares a visual resemblance with certain viral particles, yet it lacks the genetic material necessary for viral replication. Structurally, it primarily consists of protein subunits that encapsulate fragments of feline DNA. VLP-1 assumes a pivotal role in the feline immune response, particularly in the context of viral infections and vaccinations. When cats encounter viral pathogens or undergo vaccination, their immune system activates a cascade of responses. As part of this orchestrated defense, VLP-1 is synthesized and released by immune cells. Its presence serves as a clarion call, signaling the activation of the immune system, especially in response to viral antigens. Notably, VLP-1 is a benevolent mimic; it does not cause disease but instead amplifies the immune response. Its viral-like appearance acts as a catalyst, fostering a robust immunological reaction. This process primes the feline immune system to recognize and combat actual viral invaders with heightened precision and effectiveness. It is a cornerstone of the body's defense against viral threats.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.
Comments
No comments yet.